IceCure Medical Ltd (ICCM)

ICCM.................................https://stockcharts.com/sc3/ui/?s=ICCM&p=w&b=5&g=0&id=p86431144783

IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast CancerJune 23, 2026 8:10 AM
PR Newswire (US) Published in the International Journal of Surgery, globally ranked in the top three among surgery journals, the article highlights strong clinical outcomes with ProSense® cryoablation and describes thermal ablation as a "beacon of hope for patients IceCure preparing for the 2026 Japanese Breast Cancer Society meeting and planned regulatory submission for breast cancer in Japan by Terumo Corporation one of the world's top 20 medical device companiesCAESAREA, Israel, June 23, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today highlights a newly published peer-reviewed journal article presenting key clinical advantages of cryoablation over radiofrequency ablation ("RFA") for early-stage breast cancer, as the Company prepares to participate in the 34th Annual Meeting of the Japanese Breast Cancer Society ("JBCS"), taking place on June 25-27, 2026 in Kyoto, Japan. Published in the International Journal of Surgery, the article highlights the growing body of peer-reviewed evidence supporting cryoablation as a minimally invasive treatment option for appropriately selected patients with early-stage breast cancer and outlines meaningful procedural advantages compared with RFA.The International Journal of Surgery is one of the world's most prestigious peer-reviewed medical journals and currently ranked third in the world among surgical journals. The journal is highly regarded for publishing high-quality clinical research, reviews, and meta-analyses that influence surgical practice globally.The article, titled "Thermal Ablation as a Minimally Invasive Alternative to Surgery for Primary Breast Cancer," was authored by leading Japanese breast cancer specialists Drs. Masato Takahashi, Takayuki Kinoshita and Eisuke Fukuma. Professor Fukuma, a highly regarded cryoablation expert and ProSense® user at Kameda Medical Center in Japan, has performed an estimated 680 breast cancer cryoablation procedures. The publication evaluates the current clinical evidence supporting cryoablation and RFA as an option to breast-conserving surgery ("BCS"). Thermal ablation technologies have demonstrated local tumor control rates comparable to breast-conserving surgery for appropriately selected patients with small breast tumors, while offering shorter procedures, minimal scarring and improved cosmetic outcomes.Key cryoablation advantages to RFA include:During the 2025 JBCS Conference, Professor Fukuma presented a recurrence free rate of 99.02% from over 600 breast cancer patients treated with cryoablation based on data collected with follow up of up to 17 years. The RAFAELO study on RFA discussed in the article reported a 5-year ipsilateral breast tumor-free survival rate of 98.6% in 353 patients. In Japan the standard of care after BCS for invasive breast cancer (Stage I–II) is to undergo radiation therapy.Cryoablation can be performed under local anesthesia as compared to RFA which requires general anesthesia.During the procedure, cryoablation allows flexible adjustment of the ice ball size and the ice ball margin is visible, whereas RFA is hard to control due to tissue resistance and the micro bubble is vaguely visible.Multiple studies and meta-analyses reviewed by the authors found no significant differences in local recurrence or overall survival between thermal ablation, including cryoablation and RFA, and BCS in carefully selected patients with tumors measuring 2 cm or less.The authors concluded, "Ultimately, thermal ablation holds promise as a beacon of hope for patients, offering surgeons a validated method to de-escalate treatment without compromising oncological safety, while providing vastly superior aesthetic results compared to conventional BCS"."We believe the growing body of clinical evidence supporting cryoablation is accelerating physician interest worldwide, particularly following the U.S. Food and Drug Administration's marketing authorization of ProSense® for early-stage breast cancer last October," said Eyal Shamir, Chief Executive Officer of IceCure. "Japan represents one of the most important markets for ProSense®, with several investigator-initiated cryoablation studies conducted by leading Japanese physicians over the years. We are encouraged by the continued clinical validation coming from Japan and by the strong support of our exclusive distributor in Japan, Terumo Corporation, one of Japan's largest medical device companies. Together, we are working to expand access to minimally invasive breast cancer treatment options for patients across Japan."Terumo Corporation is expected to submit ProSense® for regulatory approval in breast cancer to Japan's Pharmaceuticals and Medical Devices Agency ("PMDA") in the second half of 2026, leveraging both international clinical data and Japanese physician experience with cryoablation technology.About ProSense®The ProSense® Cryoablation System is the first and only medical device to receive FDA marketing authorization for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above, including patients who are not suitable for surgical alternatives for breast cancer treatment. A full list of benefits and risks can be found on the Company's website.ProSense® is a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens the door to fast and convenient office-based procedures for breast tumors.About IceCure MedicalIceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.Forward Looking StatementThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the potential advantages of ProSense® cryoablation as compared to RFA and BCS; the growing body of clinical evidence supporting cryoablation and its potential to accelerate physician interest worldwide; the Company's preparations to participate in the 34th Annual Meeting of the JBCS; Japan as an important market for ProSense®; the expected regulatory submission by Terumo Corporation to Japan's PMDA for approval of ProSense® for breast cancer in Japan and the timing of such submission; the potential use of international clinical data and Japanese physician experience in connection with such submission; and the Company's and Terumo's efforts to expand access to minimally invasive breast cancer treatment options for patients in Japan. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2025 filed with the United States Securities and Exchange Commission ("SEC") on March 17, 2026, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.IR Contact:Email: investors @SMACM-902-5716" target="_blank" rel="nofollow">+1-888-902-5716Logo: https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg  View original content:https://www.prnewswire.com/news-releases/icecure-highlights-new-peer-reviewed-journal-article-in-leading-surgery-journal-demonstrating-cryoablations-advantages-over-radiofrequency-ablation-for-early-stage-breast-cancer-302807701.htmlSOURCE IceCure Medical Original: IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer

ICCM.........................p/m

iccm.............https://stockcharts.com/sc3/ui/?s=ICCM&p=w&b=5&g=0&id=p86431144783

what is the market opportunity here?

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional InvestorJune 17, 2026 1:14 PM
PR Newswire (US) CAESAREA, Israel, June 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into securities purchase agreements with a single healthcare focused institutional investor, for the purchase and sale of 1,833,334 ordinary shares (or ordinary share equivalents in lieu thereof), Series D Warrants to purchase up to 1,833,334 ordinary shares (the "Series D Warrants") and Series E Warrants to purchase up to 1,833,334 ordinary shares (the "Series E Warrants," and together with the Series D Warrants, the "Warrants") at a combined purchase price of $3.00 per share and accompanying Warrants in a private placement, priced at a premium to the previous Nasdaq closing price for the Company's ordinary shares. The gross proceeds from the offering are expected to be approximately $5.5 million, before deducting placement agent commissions and other estimated offering expenses. The Warrants will have an exercise price of $3.00 per share and will be exercisable immediately upon issuance. The Series D Warrants will expire five years following the date of issuance and the Series E Warrants will expire one year following the date of issuance.The closing of the offering is expected to occur on or about June 18, 2026, subject to the satisfaction of customary closing conditions. The Company currently intends to use the net proceeds from the offering for working capital and other general corporate purposes.A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.The offer and sale of the foregoing securities is being made in reliance on an exemption from the registration requirement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder, and applicable state securities laws, and the securities have not been and will not initially be registered under the Securities Act, or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to the terms of the securities purchase agreement entered into with the investor, the Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the "SEC") covering the resale of the ordinary shares and ordinary shares underlying warrants sold in the offering.The Company has also agreed, subject to receipt of shareholder approval to the extent required by applicable law and Nasdaq rules, to amend certain Series B and Series C warrants issued to the investor in March 2026 (the "March 2026 Warrants") to purchase up to an aggregate of 266,666 ordinary shares. Upon obtaining such shareholder approval, the exercise price of the March 2026 Warrants will be reduced from $16.50 per share, to $3.00 per share. The Series B Warrants will expire in June 2031 and the Series C Warrants will expire in June 2027.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About IceCure MedicalIceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the anticipated proceeds from the offering, the closing of the offering and the anticipated amendment of the March 2026 Warrants, including the receipt of any required shareholder approvals relating thereto. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2025 filed with the United States Securities and Exchange Commission ("SEC") on March 17, 2026, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.IR Contact:E-mail: investors@icecure-medical.com
Meir Peleg, CFO View original content to download multimedia:https://www.prnewswire.com/news-releases/icecure-announces-pricing-of-5-5-million-private-placement-priced-at-a-premium-to-the-market-price-with-a-single-healthcare-focused-institutional-investor-302803416.htmlSOURCE IceCure Medical Original: IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

ICCM............................p/m

IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA ClearanceJune 17, 2026 8:25 AM
PR Newswire (US) Increase driven by FDA clearance, clinical guideline support, and increased physician demand. Significant rise in number of leads for ProSense® systems generated at U.S. medical society conferences compared to last yearProSense® breast cancer cryoablation procedures have been performed in major cities across the U.S.CAESAREA, Israel, June 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), today reported a 70% increase in its U.S. active commercial install base of ProSense® for breast cancer cryoablation following U.S. Food and Drug Administration (FDA) marketing authorization in October 2025, reflecting accelerating commercial adoption, expanding physician demand and continued growth in the Company's U.S. footprint. IceCure develops and commercializes its minimally invasive cryoablation technology that destroys tumors by freezing, offering an option to surgical tumor removal for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above, including patients who are not suitable for surgery.IceCure has continued to add new ProSense® systems to its installment base at clinics and hospitals across the U.S. As adoption expands, ProSense® breast cancer cryoablation procedures have been performed in major metropolitan areas throughout the country, including Los Angeles, New York, Atlanta, Dallas, Detroit, Philadelphia, Phoenix, Memphis and many other communities.The Company had strong engagement at two of the leading breast health conferences held this earlier year, the Society of Breast Imaging ("SBI") Annual Symposium and the American Society of Breast Surgeons ("ASBrS") Annual Meeting, where IceCure generated significantly more sales leads for ProSense® systems compared to the same events in 2025, prior to FDA authorization, reflecting significantly increased interest from physicians and healthcare providers."With growing physician interest, expanding clinical acceptance, and increased patient awareness, we believe we remain in the early stages of a significant commercial opportunity for breast cancer cryoablation in the U.S.," said IceCure's Chief Executive Officer, Eyal Shamir. "We are focused on continuing to expand our installed base, supporting physicians with training and education and increasing access to ProSense® for eligible patients."In addition to regulatory approval, other factors driving demand are:Growing Clinical Acceptance - ASBrS recently updated its Resource Guide to recommend cryoablation as a local treatment option for low-risk breast cancer patients, marking an important milestone in the clinical adoption of minimally invasive breast cancer therapies. IceCure believes the updated guidance reflects growing recognition among breast surgeons and healthcare professionals of cryoablation's potential role in treating appropriately selected patients.Increasing Patient Awareness - Patient awareness of breast cancer cryoablation continues to grow as ProSense® receives broader media attention. Recent coverage by Reuters and local television news segments aired across approximately 190 CBS and CW-affiliated stations nationwide (including Boston, Philadelphia, and Chicago) have highlighted cryoablation as a minimally invasive alternative to surgery for eligible breast cancer patients. IceCure believes this increased visibility is helping educate patients and physicians about available treatment options.About ProSense®The ProSense® Cryoablation System is the first and only medical device to receive FDA marketing authorization for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above, including patients who are not suitable for surgical alternatives for breast cancer treatment. A full list of benefits and risks can be found on the Company's website.ProSense® is a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens the door to fast and convenient office-based procedures for breast tumors.About IceCure MedicalIceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.Forward Looking StatementThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: accelerating commercial momentum in the U.S. market and growth in the Company's U.S. footprint; growing physician interest in and demand for ProSense; expanding clinical acceptance and increased patient awareness of ProSense; the believe that the Company is in the early stages of a significant commercial opportunity for breast cancer cryoablation in the U.S.; the Company's focus on continuing to expand its installed base, supporting physicians with training and education, and increasing access to ProSense® for eligible patients; and the Company's belief that increased visibility regarding cryoablation is helping educate patients and physicians about available treatment options. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2025 filed with the United States Securities and Exchange Commission ("SEC") on March 17, 2026, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.IR Contact:Email: investors @SMACM-902-5716Logo - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg  View original content:https://www.prnewswire.com/news-releases/icecure-reports-70-growth-in-active-us-commercial-install-base-for-breast-cancer-cryoablation-following-fda-clearance-302803044.htmlSOURCE IceCure Medical Original: IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid RequirementMay 13, 2026 4:30 PM
PR Newswire (US) No Immediate Effect on Nasdaq Listing or Trading of the Company's Ordinary SharesCAESAREA, Israel, May 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has received a notification letter from Nasdaq Stock Market LLC ("Nasdaq") that the Company has been granted an additional 180-day compliance period, or until November 9, 2026 to regain compliance with Nasdaq's minimum bid price rule. Nasdaq's determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and the Company's written notice of its intention to cure the deficiency during the second compliance period and if necessary, by effecting a reverse share split.In a notification letter dated November 12, 2025, Nasdaq had first informed the Company that, based on the previous 30 consecutive business days, the Company's ordinary shares no longer met the minimum $1.00 bid price per share requirement and in accordance with Nasdaq's Listing Rules, the Company was provided 180 calendar days, or until May 11, 2026, to regain compliance. The Company did not regain compliance with the minimum $1.00 bid price per share requirement during the first 180-calendar-day compliance period and submitted a written request to the Nasdaq's staff to afford it an additional 180-day compliance period to cure the deficiency, which it was granted in a notification letter dated May 12, 2026.If at any time before November 9, 2026, the closing bid price of the Company's ordinary shares is at least $1.00 per share for a minimum of 10 consecutive business days, the Company will regain compliance with this Nasdaq rule and this matter will be closed. However, Nasdaq may, in its discretion, require the Company's ordinary shares to maintain a bid price of at least $1.00 for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance.This current notification from Nasdaq has no immediate effect on the listing or trading of the Company's ordinary shares, which will continue to trade on the Nasdaq Capital Market under the symbol "ICCM."About IceCure MedicalIceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia. Forward-Looking Statements:This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, IceCure is using forward-looking statements when it discusses regaining compliance with Nasdaq's continued listing requirements, and the timing and effect thereof as well as potentially effecting a reverse share split. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Because such statements deal with future events and are based on IceCure's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of IceCure could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in IceCure's Annual Report on Form 20-F filed with the SEC on March 17, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, IceCure disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.Investor Contact:Email: investors @Reidman-6914Logo - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg View original content:https://www.prnewswire.com/news-releases/icecure-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-requirement-302771474.htmlSOURCE IceCure Medical Original: IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026May 6, 2026 8:30 AM
PR Newswire (US) CAESAREA, Israel, May 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the three months ended March 31, 2026 before the Nasdaq Stock Market opens on Tuesday, May 12, 2026. The Company will also discuss such results and other corporate developments on a conference call at 11:00 a.m. EDT on the same day.  Conference call & webcast info:
Tuesday, May 12, 2026, at 11:00 am EDT
US: 1-888-407-2553
Israel/International: +972-3-918-0696
A live webcast will be available at:  https://www.veidan-conferencing.com/icecure-investors
A recording of the webcast will be available at: ir.icecure-medical.comAbout IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the United States, Europe and Asia.Forward Looking Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the timing for announcing its financial and operating results for the three month ended March 31, 2026 and the related conference call. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission ("SEC") on March 17, 2026, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.IR Contact:Email: investors @Reidman-6914Logo - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg View original content:https://www.prnewswire.com/news-releases/icecure-medical-to-report-first-quarter-2026-financial-and-operating-results-on-may-12-2026-302764075.htmlSOURCE IceCure Medical Original: IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025April 21, 2026 8:30 AM
PR Newswire (US)

The Company's participation at the Society of Breast Imaging Symposium and other upcoming medical conferences are timely as commercial momentum acceleratesCryoablation cost analysis study from Massachusetts General Hospital featuring ProSense® demonstrated 50% reduction in cost vs. lumpectomy won SBI 2026 Abstract AwardCAESAREA, Israel, April 21, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it expects to report U.S. revenue of ProSense® systems and cryoprobes increased more than 30% in the first quarter of 2026 compared the same period last year, based on preliminary, unaudited estimates.
 The performance in the U.S. represents the adoption of ProSense® immediately following the U.S. Food and Drug Administration's ("FDA") clearance of ProSense® for the local treatment of low-risk breast cancer in women aged 70 and above in October 2025. The Company experienced this rising enthusiasm at the Society of Breast Imaging ("SBI") 2026 Symposium ("SBI 2026"), which was held in Seattle, Washington from April 16 to 19, 2026. IceCure exhibited ProSense® cryoablation technology and participated in a hands-on physician training workshop.Following the FDA's clearance of ProSense® for early-stage breast cancer, IceCure continues to expand its installed base of ProSense® systems in the U.S., including placements at leading academic and research hospitals, supported by a robust and expanding pipeline of prospective customers, which the Company expects to close with new system sales in the second quarter of 2026."IceCure is seeing a meaningful shift in the treatment landscape for early-stage breast cancer, with cryoablation gaining increasing attention from physicians, healthcare systems, and patients," said Eyal Shamir, Chief Executive Officer of IceCure. "We believe this growing momentum is reflected in our strong commercial performance in the U.S., as well as in the expanding number of systems installed at some of the most prestigious teaching and research hospitals in the U.S. Additionally, we believe the high level of engagement at SBI 2026, combined with independent, award-winning data demonstrating the significant cost benefits of cryoablation, further supports our view that this technology is advancing toward becoming a standard-of-care option for indicated patients."Award Winning AbstractAt SBI 2026, an award-winning abstract titled "Cost Analysis of Percutaneous Cryoablation versus Breast Conserving Surgery for the Treatment of Breast Cancer: Implication for Cost Efficacy-based Treatment Strategy" was presented by Matt Hoyer, M.D., of Massachusetts General Hospital. The study received the Wendell Scott Research Award, which recognizes the most outstanding abstract submitted by a breast imaging fellow. The analysis, which evaluated ProSense® as one of two liquid nitrogen-based cryoablation systems, demonstrated that cryoablation may reduce total treatment costs by more than 50% compared to breast-conserving surgery. The findings also highlighted cryoablation as a viable alternative for well-selected, low-risk early-stage breast cancer patients, building on promising treatment outcomes demonstrated in prior studies, including IceCure's ICE3 trial. In addition to highlighting optimized outpatient treatment, faster recovery, and improved patient quality of life, the abstract emphasized cryoablation's alignment with value-based low cost care and its potential to expand the role of radiologists in multidisciplinary cancer treatment.How-To Cryoablation Workshop 
Part of SBI 2026's scientific programming included the workshop, "How I Do It – Cryoablation: Working It Up and Freezing it Out," led by Luz A. Venta, M.D., FACR, FSBI, of Weill Cornell Medical College, and Robert C. Ward, M.D., of the Warren Alpert Medical School of Brown University. The session provided practical, real-world guidance on integrating cryoablation into clinical practice. Dr. Venta's portion focused on optimizing diagnostic imaging workups prior to cryoablation, including protocols for evaluating masses, calcifications, asymmetries, and associated findings. Dr. Ward, who will be the co-primary investigator of IceCure's upcoming post-market surveillance study, the ChoICE trial, reviewed procedural techniques, clinical indications, and supporting data for cryoablation, as well as strategies to maximize benefits while minimizing risks and addressing potential barriers to broader adoption. The session concluded with an interactive Q&A, offering attendees deeper insight into implementation and best practices.The Company expects to report its full operating and financial results for the first quarter of 2026 on Thursday, May 14, 2026.  Details for the conference call and webcast will be provided in a separate press release in early May. The preliminary financial information above regarding an increase in the Company's U.S. revenue of ProSense ® systems and cryoprobes for the first quarter of 2026 has been prepared solely on the basis of information that is currently available to, and that is the responsibility of, management and is based upon Company estimates and remains subject to, among other things, the completion of IceCure's quarterly financial closing procedures and final adjustments, which may impact the results and expectations set forth above.About ProSense®
The ProSense® Cryoablation System is the first and only medical device to receive FDA marketing authorization for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above, including patients who are not suitable for surgical alternatives for breast cancer treatment. A full list of benefits and risks can be found on the Company's website.ProSense® is a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens the door to fast and convenient office-based procedures for breast tumors.About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.Forward Looking StatementThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the expected increase in U.S. revenue of ProSense® systems and cryoprobes in the first quarter of 2026 compared to the first quarter of 2025, which are subject to, among other things, the completion of IceCure's quarterly financial closing procedures and final adjustments, which may impact the results and expectations set forth above; the Company's expectations regarding closing new system sales in the second quarter of 2026; the Company's belief that commercial momentum reflects a meaningful shift in the treatment landscape for early-stage breast cancer; the potential for cryoablation to become a standard-of-care option for indicated patients; and the Company's expectations regarding the timing of reporting its full operating and financial results for the first quarter of 2026. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on March 17, 2026, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.IR Contact:E-mail: investors @Reidman-6914Logo  - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg



View original content:https://www.prnewswire.com/news-releases/icecure-participates-in-society-of-breast-imaging-symposium-2026-as-us-prosense-revenue-increases-by-30-in-first-quarter-of-2026-compared-to-first-quarter-of-2025-302747230.htmlSOURCE IceCure Medical

Original: IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

New news,

"https://finance.yahoo.com/sectors/healthcare/articles/icecure-reports-positive-5-top-123000614.html"

Boing X 2

If Susie Wiles uses this and it works this stock will go to the moon

American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast CancerMarch 9, 2026 8:30 AM
PR Newswire (US)

IceCure's ICE3 study and the FDA Advisory Panel's favorable vote on ProSense® cryoablation's benefit-risk profile for low-risk breast cancer played a key role in the ASBrS 2026 Resource Guide updateNew medical society guidance expected to further accelerate commercial adoption of ProSense® following FDA-clearance for low-risk breast cancer in October 2025CAESAREA, Israel, March 9, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the American Society of Breast Surgeons' ("ASBrS") updated 2026 "Resource Guide on the Use of Transcutaneous and Percutaneous Ablation for the Treatment of Benign and Malignant Tumors of the Breast" recommends cryoablation as an option for selected patients with biologically low-risk early-stage breast cancer. The updated guidance represents an important step toward broader clinical adoption of IceCure's ProSense® cryoablation system, which received U.S. Food and Drug Administration ("FDA") marketing clearance in October 2025 for the treatment of low-risk breast cancer in patients aged ≥70 years, with tumors measuring ≤1.5 cm, who are treated with adjuvant endocrine therapy. ProSense® is the first and only FDA cleared medical device for the treatment of breast cancer.
"We believe this recognition by the ASBrS, a leading professional society, further validates cryoablation's role in modern breast cancer care and positions ProSense® as an option that prioritizes outcomes, cosmetic results, and patient choice," said Eyal Shamir, IceCure's Chief Executive Officer. "The ASBrS Resource Guide on percutaneous ablation compliments their recent guidance for breast-conserving treatment, emphasizing preservation, de-escalation, and individualized care. Cryoablation aligns naturally with these principles by providing minimally invasive, breast-preserving local tumor control without surgical excision."IceCure's Vice President of Sales for North America, Shad Good, added, "We believe ASBrS's new guidance will further raise awareness of and confidence in cryoablation among patients and breast surgeons, who develop and oversee breast cancer patients' treatment plans. We expect these developments, as well as the established CPT III reimbursement code, will help further accelerate commercial adoption and drive continued momentum in ProSense® system placements and procedure volumes."The ASBrS 2026 Resource Guide continues to recognize cryoablation as a validated, cosmetically favorable treatment for benign fibroadenomas and now identifies it as a carefully selected, FDA-approved option to surgery for biologically low-risk early-stage breast cancer in older patients. The guide indicates that cryoablation must be considered in the context of a comprehensive treatment plan with input from a multidisciplinary team. The ASBrS recommendations align clinical evidence, FDA authorization, and multidisciplinary care principles into a unified framework for the use of breast cryoablation.Based on data from the American Cancer Society, ProSense® addresses a U.S. breast cryoablation patient population of approximately 200,000 women annually, including an estimated 47,245 early-stage, low-risk breast cancer patients aged 70 and over, approximately 90,300 patients who are not candidates for breast cancer surgery, and roughly 63,200 patients with fibroadenomas who opt for excision.About ProSense®The ProSense® Cryoablation System is the first and only medical device to receive FDA marketing authorization for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above, including patients who are not suitable for surgical alternatives for breast cancer treatment. A full list of benefits and risks can be found on the Company's website.ProSense® is a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens the door to fast and convenient office-based procedures for breast tumors.About IceCure MedicalIceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia.Forward Looking StatementThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the expected impact of the of the ASBrS 2026 Resource Guide update  on physician adoption, patient access, reimbursement coverage, and commercial adoption of ProSense®; the Company's belief that ProSense® is positioned as a treatment option that prioritizes outcomes, cosmetic results, and patient choice; that the ASBrS guidance is expected to further accelerate commercial adoption of ProSense® following FDA-clearance for low-risk breast cancer in October 2025; and the Company's expectations regarding the role of cryoablation as a minimally invasive treatment option for appropriately selected breast cancer patients. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.IR Contact:Email: investors @Reidman-6914Logo - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg



View original content:https://www.prnewswire.com/news-releases/american-society-of-breast-surgeons-asbrs-resource-guide-update-recommends-cryoablation-for-low-risk-breast-cancer-302708105.htmlSOURCE IceCure Medical

Original: American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer

IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast FibroadenomasMarch 2, 2026 8:30 AM
PR Newswire (US)

Treatment with ProSense® resulted in 92.9% volume reduction of fibroadenoma one-year post-cryoablationFindings may impact treatment guidelines issued by medical societies for large non-cancerous breast tumors; study is believed to be the first to evaluate larger lesions and use multiple cryoprobe relocationsProSense® Cryoablation has FDA-clearance for fibroadenomasCAESAREA, Israel, March 2, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the publication of an independent, investigator-initiated study evaluating ProSense® for the treatment of non-cancerous breast tumors,  or fibroadenomas. The study, titled "Cryoablation for fibroadenoma with liquid nitrogen-based system: A retrospective analysis of prospectively collected data," was published in the peer-reviewed journal PLOS One.
Fibroadenoma is the most common benign breast lesion identified through core needle biopsy. Up to 10% of women will have a fibroadenoma at some point in their lives, according to the Cleveland Clinic. Surgical excision is currently the standard of care for many fibroadenomas, particularly for larger lesions or those causing discomfort. IceCure estimates that cryoablation could address approximately 63,000 cases of fibroadenoma excision in the U.S. annually.  "We believe this publication is very significant because it reinforces the safety and effectiveness of ProSense® cryoablation for fibroadenomas and may contribute to updates in treatment guidelines for non-cancerous breast tumors issued by medical societies in key markets where ProSense® is used, including the American Society of Breast Surgeons," said Eyal Shamir, IceCure's Chief Executive Officer. "Previous studies supporting cryoablation for fibroadenomas were often limited to lesions 4 centimeters or smaller, and many were published more than a decade ago. This study is unique in that it includes a large patient cohort and evaluates larger lesions using multiple cryoprobe relocations. We are grateful to the study's investigators for their pursuit of improved outcomes for patients and their use of ProSense® for their study."The study was conducted at the Premier Med Healthcare, Training, and Research Institute in Hungary and led by Dr. Teodora Filipov and Dr. Pál Ákos Deák. The investigators concluded that cryoablation with a liquid nitrogen system, specifically ProSense®, proved safe and effective, demonstrating a median volume reduction of 80.6% at approximately six months and 92.9% at one-year post-treatment. The study further found that sequential cryoprobe relocations preserve safety and efficacy. ProSense® cryoprobes can be relocated up to three times per patient, per procedure enabling physicians to fully treat large or multifocal lesions through complete ablation coverage.IceCure believes these findings further support the growing clinical adoption of minimally invasive cryoablation as an alternative to surgical excision for benign breast tumors, particularly for women seeking minimal scarring and short procedure times.About ProSense®The ProSense® Cryoablation System is the first and only medical device to receive FDA marketing authorization for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above, including patients who are not suitable for surgical alternatives for breast cancer treatment. A full list of benefits and risks can be found on the Company's website.ProSense® is a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens the door to fast and convenient office-based procedures for breast tumors.About IceCure MedicalIceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the United States, Europe and Asia.Forward Looking StatementThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the potential number of cases of fibroadenoma excision that cryoablation could address in the U.S. annually; the potential impact of the study's findings on future treatment guidelines for non-cancerous breast tumors; the possibility that the results may contribute to updates by medical societies such as the American Society of Breast Surgeons; and the expectation that these findings will further support the growing clinical adoption of ProSense as an alternative to surgical excision for benign breast tumors. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission ("SEC") on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.IR Contact:Email: investors @Reidman-6914Logo - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg



View original content:https://www.prnewswire.com/news-releases/icecure-medical-reports-independent-study-published-in-plos-one-demonstrating-prosense-cryoablation-safe-and-effective-in-treatment-of-breast-fibroadenomas-302701021.htmlSOURCE IceCure Medical

Original: IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas

IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026February 23, 2026 8:30 AM
PR Newswire (US)

Previously released interim data from 111 patients demonstrated ProSense® is safe and effective in destruction of kidney tumors with 88.7% recurrence-free rateIncidence of kidney cancer is growing worldwide, with an estimated 400,000 new cases globally; over 80,000 of which are in the U.S. alone highlighting a growing unmet needProSense® is approved for benign and malignant kidney tumors in the U.S., Europe, and numerous other countriesCAESAREA, Israel, Feb. 23, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the completion of its last patients' five-year follow up evaluation in its ICESECRET clinical trial of ProSense® for the treatment of small renal masses ("SRMs") in kidney cancer patients.  ICESECRET, a prospective, multicenter, single-arm clinical trial, was performed at Bnai Zion Medical Center in Haifa, Israel and Shamir Medical Center in Be'er Ya'akov, Israel and is led by Principal Investigator Prof. Halahmi Sarel. The trial included 114 patients (138 lesions) with localized SRMs of ≤5 cm ablated with ProSense® cryoablation under CT guidance. Follow-up visits were performed at six weeks, six months, one year and then annually up to five years after the procedure using ProSense®. During follow-up visits, data related to local recurrence, based on CT imaging, was collected. Safety was determined by monitoring procedure-related adverse events throughout the study."Interim three-year data from ICESECRET, which was collected from 111 eligible patients at the time, was presented a year ago and demonstrated the strong potential of ProSense® cryoablation as a safe and effective option for patients who are otherwise ineligible for kidney preserving surgery, a growing unmet need," stated Eyal Shamir, IceCure's Chief Executive Officer. "Importantly, ProSense® already has regulatory approval to treat kidney cancer in key markets including the U.S. and Europe. We are now working closely with Prof. Sarel on data analysis and publication, with the intention of bringing this minimally invasive procedure to patients in Israel with kidney cancer."SRMs are increasingly detected due to widespread imaging and represent a growing clinical challenge, particularly among elderly patients and those with comorbidities who are not suitable candidates for surgery. Minimally invasive, nephron-sparing treatment options that preserve kidney function, while effectively controlling tumors, are critically needed.About ProSense®The ProSense® Cryoablation System is the first and only medical device to receive FDA marketing authorization for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above, including patients who are not suitable for surgical alternatives for breast cancer treatment. A full list of benefits and risks can be found on the Company's website.ProSense® is a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens the door to fast and convenient office-based procedures for breast tumors.About IceCure MedicalIceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.Forward Looking StatementThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the expected timing of the final analysis of data from the ICESECRET study, including the expectation that results will be available by the end of the first half of 2026; the clinical performance, safety, efficacy and recurrence-free rates associated with ProSense® cryoablation treatment of kidney tumors; the potential of ProSense® as a safe and effective treatment option for patients with SRMs and those ineligible for kidney-preserving surgery; and the anticipated clinical adoption, utilization and expansion of ProSense® in the treatment of kidney cancer. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.Logo: https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpgIR Contact:
Michael Polyviou
732-232-6914 
investors@icecure-medical.com



View original content:https://www.prnewswire.com/news-releases/icecure-medical-successfully-completes-5-year-patient-follow-up-in-icesecret-kidney-cancer-cryoablation-study-final-analysis-expected-in-second-quarter-of-2026-302694500.htmlSOURCE IceCure Medical

Original: IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026

Another new article.

"https://finance.yahoo.com/news/icecure-announces-thomas-hospital-infirmary-133000846.html"

Slowly gaining traction.

Boing x 2

New article,

æhttps://www.ainvest.com/news/icecure-assessing-mover-infrastructure-play-minimally-invasive-breast-cancer-treatment-2602/

Boing X 2

IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones AchievedFebruary 9, 2026 4:30 PM
PR Newswire (US)

Ronen Tsimerman will continue as CFO until successor is appointedCAESAREA, Israel, Feb. 9, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that after nearly a decade of service with IceCure, Chief Financial Officer Ronen Tsimerman has informed the Company of his decision to leave the Company to pursue new opportunities. The Company has initiated a search for a new Chief Financial Officer and has identified compelling candidates with significant experience commercializing disruptive technologies. Some candidates have recently advanced in the selection process to interviews with IceCure's Board of Directors. Mr. Tsimerman will continue in his role until a successor is appointed, to ensure a smooth transition.
"Ronen has been a valued contributor over the years, and his skilled financial and operational leadership allowed IceCure Medical to achieve several key milestones, including our listing on the Nasdaq, fundraisings to support the completion of our ICE3 study, the largest of its kind for cryoablation, and the subsequent U.S. Food and Drug Administration marketing clearance of ProSense® for low-risk breast cancer, in late 2025 ," stated IceCure's Chief Executive Officer, Eyal Shamir. "Ronen has been a trusted colleague and friend to our entire team and we wish him well in his future endeavors and are pleased to have his continued support over the next few months as we transition to a new CFO.""I am extremely proud of the great work we've accomplished at IceCure. Our mission and the collaborative work with regulatory agencies, medical societies, caregivers and patients across the globe to bring the first and only on-label treatment in the U.S. for the minimally invasive treatment of low-risk breast cancer is truly an amazing accomplishment," Mr. Tsimerman stated. "I thank Eyal and the entire team for their professional excellence and partnership in advancing the Company's mission."About ProSense®The ProSense® Cryoablation System is the first and only medical device to receive FDA marketing authorization for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above, including patients who are not suitable for surgical alternatives for breast cancer treatment. A full list of benefits and risks can be found on the Company's website.ProSense® is a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens the door to fast and convenient office-based procedures for breast tumors.About IceCure MedicalIceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia.Forward Looking StatementThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the timing and completion of the planned transition of its Chief Financial Officer, the search for and appointment of a successor Chief Financial Officer, and the Company's expectations regarding continuity of financial leadership and operations during the transition period. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.IR Contact:Email: investors @Reidman-6914Logo - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg



View original content:https://www.prnewswire.com/news-releases/icecure-announces-planned-departure-of-cfo-following-nine-years-of-service-and-key-milestones-achieved-302682657.htmlSOURCE IceCure Medical

Original: IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

"https://investorshub.advfn.com/stock-market/NASDAQ/icecure-medical-ICCM/stock-news/97704609/icecure-celebrates-american-society-of-breast-surg"

Getting closer to standard of care.

Boing X 2

Been watching this to see if they can regain compliance price but this just sunk the boat 

You can GAURANTEE a huge RS is coming ! That last PR is a death nail for current shareholders 

Looking for raises and the stock is performing like crap.These guys got balls.

Made my third major purchase today. Will wait on further news before my last buy.

Checked on Earnings Whisper Numbers and they show Feb 18th with -.04cents. If that is anywhere near correct that is a .26 cent improvement year over year.

First quarter could end up being a back order situation if interest is really high.

Merry Christmas and a Happy New Year to all.

Boing X 2

If I am correct that is is Mayo Clinic, they have 60 locations.

Funds and EtF's have no clue yet. Will be interesting to see the actual 4th quarter results and what is said. If they have great 4th quarter sales it makes the money go further and then 1st quarter really can take off. All IMHO.

By the time the big boys wake up, shares are going to be likely hard to come by.

Boing X 2

Great news,

I am guessing the hospital chain is Mayo Clinic. If right, they are setting the new standard.

Boing X 2

IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer

https://finance.yahoo.com/news/icecure-expected-report-record-fourth-133000676.html

ProSense® systems are being sold and installed at new locations across North America, including some of the most highly regarded medical institutions in the United States

Here is why 50,000 interventional radiologists is likely very important.

"Interventional Radiologists (IRs) are medical doctors who specialize in diagnosing and treating a wide range of conditions using minimally invasive, image-guided procedures.

They use real-time imaging technologies—like X-rays (fluoroscopy), CT scans, ultrasound, and MRI—to guide small instruments, such as needles and catheters, through the skin or blood vessels to a target area in the body.

Here is an overview of the types of procedures an Interventional Radiologist is allowed to perform, categorized by the area of treatment:

💉 Vascular & Circulatory System Procedures
These procedures deal with blood vessels (arteries and veins):

Angiography and Angioplasty/Stenting: Diagnosing and treating narrowed or blocked blood vessels. This involves using a balloon to open the vessel (angioplasty) and often placing a small mesh tube (stent) to keep it open.


Embolization: Blocking blood flow to a specific area. This is used to stop bleeding (e.g., in trauma or postpartum hemorrhage), shrink tumors (by cutting off their blood supply), or treat conditions like uterine fibroids (Uterine Fibroid Embolization) and varicoceles.


Thrombolysis/Thrombectomy: Dissolving or removing blood clots from arteries or veins, often used for deep vein thrombosis (DVT) or pulmonary embolism (PE).

IVC Filter Placement/Retrieval: Placing a small filter in the largest vein (inferior vena cava) to catch blood clots and prevent them from reaching the lungs.

Venous Access: Placement of long-term catheters, ports, or dialysis access devices.

⚕️ Cancer Treatment (Interventional Oncology)
IRs are key members of the cancer treatment team, often performing:

Tumor Ablation: Destroying tumors using extreme heat (Radiofrequency Ablation - RFA, Microwave Ablation) or cold (Cryoablation) delivered through a needle.

Chemoembolization (TACE) & Radioembolization (Y-90): Highly targeted therapies for liver cancer where chemotherapy or radioactive particles are delivered directly into the arteries feeding the tumor.


🔬 Biopsies and Drainage
These are fundamental IR procedures:

Image-Guided Biopsy: Using a needle under imaging guidance (CT, ultrasound, etc.) to collect tissue samples from almost any organ (lung, liver, kidney, bone, etc.) for diagnosis.

Abscess/Fluid Drainage: Placing a catheter to drain abnormal fluid collections, such as abscesses, cysts, or excess fluid around the lungs (thoracentesis) or in the abdomen (paracentesis).

🦴 Spine and Musculoskeletal Procedures
Vertebral Augmentation (Vertebroplasty/Kyphoplasty): Treating painful spinal compression fractures by injecting bone cement into the collapsed vertebra.

Pain Management Injections: Targeted injections for pain, such as nerve blocks or facet joint injections, using imaging guidance for precision.

🦠 Non-Vascular Organ Interventions
Biliary Interventions: Placing drains or stents to relieve blockages in the bile ducts, often caused by stones or tumors.

Genitourinary Interventions: Placing tubes (nephrostomy) or stents to relieve urinary blockages, often caused by kidney stones or tumors.

Gastrointestinal Access: Placement of feeding tubes directly into the stomach (gastrostomy) or small intestine (jejunostomy).

Key Takeaway

Interventional Radiologists are essentially minimally invasive procedure specialists. Their unique authority comes from their expertise in medical imaging (diagnosing conditions) combined with their specialized training in image-guided access and treatment (performing the procedure), which often allows for treatments that replace the need for traditional, open surgery."

It gives them another tool to treat cancer. If they adopt it for use it is big.

Boing X 2

I added another major position just now.

50,000 radiologist listening to 4 of our abstracts. If 1percent buy the x-sense that would be 500 units.

2.5 million new breast cancers a year. Not counting all the other uses and total tumor cases a year.

First time I have started picking up posts from around the world from investment clubs looking at ICCM to buy.

Big boy funds have yet to wake up to this stock.

H- LI who is on the board was head of 10 cent. He is the head of Epoch Partners who owns almost 26M shares. I doubt he will want to see the stock hurt.

Research what potential A1 has to Icecure medical. Too long to post here.

Boing X 2

IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

https://finance.yahoo.com/news/icecures-prosense-cryoablation-featured-4-133000193.html

Abstracts presented include 3 studies involving 263 patients, adding to a growing body of evidence across diverse patient populations supporting broader adoption of ProSense®

Rarely a ticker looks good on all time frames from 1 day to 1 year with an extremely similar past of macd reversal and is coming off bottom when you find it. Seek them with patience!
Good skill everyone!

ICCM,bought .70,buys 4Xs sells,hit zero borrow today,reversal candles off 52week low,started moving fairly freely today,watch for buying volume surges now as death hr is ending in 15min
https://investorshub.advfn.com/stock-market/NASDAQ/icecure-medical-ICCM/trades

First case ProSense was used on in Turkey was on an adrenal gland.

It looks like this has the potential for many uses.

Boing X 2

Big Boys have a list already!

Found this. "Looking forward, it appears increasingly plausible that we may be on the brink of a paradigm shift in early breast cancer management. The ASBrS membership selection of the ICE3 study as having the most scientific impact suggests that we are getting closer to adopting this newer, patient centric, cost-effective approach to treating early breast cancer. At UCLA, we now have a Registry for patients who meet the ICE3 criteria for cryoablation and choose this option. We anticipate delving deeper into the science of cryoablation across various contexts to uncover additional applications of this innovative technology in our research pursuits.

If they don't have the machines it looks like they will likely budget for them.

Boing X 2

The FDA approval could not be better timing.

Most medical facilities are in the process of budgeting for medical equipment for 2026. It appears the doctors rally want this procedure available having listened to the FDA hearings.

If the doctors petition the hospitals to get this equipment in 2026 it could well take off.

I remember the eye surgeon getting the hospital to get the first eye surgery laser during the budgeting process.

Boing X 2

I have been thinking about this new article and the more I think about it,I think this study has the potential to make this the standard of care.

In other words because of the longer survival rate it should be the standard to use the freezing iin conjunction with the chemo. Time will tell.

Boing X 2

This is BIG!

"https://finance.yahoo.com/news/icecures-cryoablation-system-combined-radiation-133000826.html"

As one who has a lung tumor in remission so far, this is very good news.

Boing X 2

"$200,000 in delayed shipments moving to Q3 2025 due to temporary logistics issues related to the Israel-Iran conflict."

Boing X 2

This company has the lousiest PR team I think have ever seen

Added major position today. Wed and Thursday they meet with institutional analysts. Once they find out what all they are doing, I think it is going to get their attention.

The FDA likely gave them a 7 year advantage by saying there would be no approval unless they would do the same five year breast study and gave a second advantage that anyone wanting approval would have to use the same size needle. There could be patent violations if they tried that.

Glad to see we will be getting recurring revenues with the disposable needles.

I expect the Japan approval to almost be a rubber stamp with the FDA approval.

I see earrings estimate for third quarter at ..05 cents. That should help while they crank up sales;

A big one is the 190M women with pain from endometriosis and being able to relieve that pain.

Boing X 2

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

https://finance.yahoo.com/news/icecures-prosense-showcased-tme-fall-123000274.html

ICCM................................https://stockcharts.com/h-sc/ui?s=ICCM&p=W&b=5&g=0&id=p86431144783

https://ir.icecure-medical.com/news-events/press-releases/detail/190/icecure-receives-fda-marketing-authorization-for-prosense-cryoablation-for-the-treatment-of-low-risk-breast-cancer-in-women-aged-70-and-above

Approved and currently halted

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

https://finance.yahoo.com/news/icecures-prosense-featured-cirse-2025-123000338.html

Mon, September 22, 2025 at 3:30 PM GMT+3

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

https://finance.yahoo.com/news/icecure-granted-notice-allowance-u-123000158.html


The invention is designed to improve cryoprobe extraction, further reducing risk of tissue trauma, leading to lower costs and improved patient experience

XSense™ System with Cryoprobes recently received regulatory approval in the U.S. and Israel

CAESAREA, Israel, Sept. 18, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent titled "Cryoprobe".

"Our industry-leading liquid-nitrogen-based cryoablation platform has been further advanced with this latest invention, a cryoprobe technology," stated IceCure's Chief Executive Officer, Eyal Shamir. "There is an abundance of data, much of it from independent studies, showing that minimally invasive cryoablation procedures with our flagship ProSense® system have resulted in an improved patient experience with excellent medical outcomes. This new cryoprobe technology, which is integrated in our next-generation XSense™ system, further reduces any potential risk of tissue trauma as the cryoprobe is extracted from the patient at the end of the short, minimally invasive outpatient procedure."

This invention introduces a novel method for safely and efficiently extracting the cryoprobe after tissue freezing during cryoablation procedures. The cryoprobe's tip is integrated with a heater, temperature sensor, and controlled gas pulses, enabling precise estimation and management of the cryoprobe's external surface temperature—even while embedded in frozen tissue. Designed to be compatible with a wide range of XSense™ system cryoprobe types, the new cryoprobe technology is a versatile solution for multiple clinical scenarios.

Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals

IceCure Medical Ltd. (NASDAQ: ICCM) has received regulatory approval from Israel's Ministry of Health for its next-generation XSense™ cryoablation system across multiple oncology indications, including breast cancer treatment. The approval encompasses general surgery, dermatology, neurology, thoracic surgery, ENT, gynecology, oncology, proctology, and urology applications. XSense™ had previously received FDA clearance in mid-2024 for all indications approved for the company's flagship ProSense® system.

"We believe that this latest regulatory approval for our next-generation cryoablation system reaffirms IceCure's leadership position in liquid-nitrogen based cryoablation," said Eyal Shamir, CEO of IceCure Medical. "The minimally invasive cryoablation option that we offer across a broad range of indications can de-escalate cancer care, reduce treatment costs for payers, and accelerate recovery time for patients."

The XSense™ platform technology provides minimally invasive tumor destruction by freezing, targeting benign and cancerous lesions in breast, kidney, lung, and liver applications. IceCure's liquid-nitrogen-based systems offer a transportable design enabling office-based procedures for breast tumors with reduced surgical risks and complications.

Cancer cure device News Israel approval,fda approved already ,pre mkt spike 1.25,insiders 50%,institutions buying up 140%,target 2.59,I am in 1.04
Good skill everyone!

IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications

https://finance.yahoo.com/news/icecure-receives-regulatory-approval-israel-123000831.html

Approved for a broad range of indications including in gynecology, oncology and general surgery

CAESAREA, Israel, Sept. 15, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced it has received regulatory approval from the Medical Device Division of Israel's Ministry of Health ("AMAR") for its next-generation single cryoprobe cryoablation system, the XSense™ System and CryoProbes.

As of mid-2024, XSense™ and its cryoprobes have also received regulatory clearance in the United States from the U.S. Food and Drug Administration ("FDA") for all of the indications for which ProSense®, the Company's flagship cryoablation system, has already received from the FDA.

"We believe that this latest regulatory approval for our next-generation cryoablation system reaffirms IceCure's leadership position in liquid-nitrogen based cryoablation," stated IceCure's Chief Executive Officer, Eyal Shamir. "The minimally invasive cryoablation option that we offer across a broad range of indications can de-escalate cancer care, reduce treatment costs for payers, and accelerate recovery time for patients."

"We are particularly pleased with the breast cancer indication approval in Israel, as we believe the growing body of evidence on cryoablation as a minimally invasive option for breast cancer supports accelerated commercial adoption," Shamir added.

XSense™ is now approved in Israel for all indications for which ProSense® has already received approval in Israel, including general surgery, dermatology, neurology, including cryoanalgesia, thoracic surgery, ENT (ear, nose, throat), gynecology, oncology (including benign and malignant breast tumors), proctology and urology.

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

https://finance.yahoo.com/news/two-publications-independent-thermac-trial-123000068.html

Article published in European Journal of Surgical Oncology focused on cosmetic outcomes and patient satisfaction reports 95% of patients were very satisfied or satisfied with thermal ablation

Article published in Radiology demonstrated that cryoablation with ProSense® achieved the highest complete ablation rate compared to alternatives with no adverse events

Great study,

https://investorshub.advfn.com/stock-market/NASDAQ/icecure-medical-ICCM/stock-news/96761580/icecures-prosense-substantially-reduces-abdominal

Boing X 2